Prolia injection sits at the center of this dementia and brain health question.
Prolia — the brand name for denosumab — is one of the most effective injectable treatments for osteoporosis available today. In clinical trials, it reduced new vertebral fractures by 68% over three years, and ten-year extension data showed continuous bone mineral density gains with sustained low fracture rates. For the millions of older adults managing both cognitive decline and bone loss, those numbers sound like a straightforward win. But there is a serious catch that every patient, caregiver, and clinician needs to understand before starting this drug: stopping Prolia can be more dangerous than never taking it at all.
When patients discontinue Prolia without transitioning to another bone-protecting medication, they can lose all of their treatment-associated bone density gains at the lumbar spine and total hip within just 12 months. Roughly 1 in 14 patients who stop without a follow-up therapy experience rebound-associated fractures, and up to 10% suffer multiple vertebral fractures. For someone living with dementia — where medication adherence is already a daily struggle and a single fall can be catastrophic — this rebound effect raises questions that go well beyond standard osteoporosis management. This article breaks down what the clinical evidence actually shows, who benefits most, who faces the greatest risks, what the drug costs, and what the arrival of cheaper biosimilars in 2025 means for families weighing their options.
Table of Contents
- How Effective Is Prolia Injection for Bone Loss, and What Do the Trial Results Actually Show?
- The Rebound Effect — Why Stopping Prolia Can Trigger a Cascade of Fractures
- Why the Rebound Problem Matters More in Dementia Care
- What Does Prolia Cost, and Are Biosimilars a Realistic Alternative?
- Side Effects Beyond the Rebound — What Else Should Patients and Caregivers Watch For?
- The Legal Landscape Around Prolia
- What Comes Next for Bone Loss Treatment in Aging Populations
- Conclusion
- Frequently Asked Questions
How Effective Is Prolia Injection for Bone Loss, and What Do the Trial Results Actually Show?
The landmark study behind Prolia’s FDA approval on June 1, 2010, was the FREEDOM trial — a massive randomized controlled study of 7,868 postmenopausal women between the ages of 60 and 90. Over 36 months, women receiving a 60 mg subcutaneous injection every six months saw new vertebral fractures drop from 7.2% in the placebo group to just 2.3% in the denosumab group. Hip fractures were also reduced, from 1.2% to 0.7%, and nonvertebral fractures fell from 8.0% to 6.5%. Those are not marginal improvements. For a twice-yearly injection, the fracture reduction was among the strongest seen in any osteoporosis therapy.
The benefits did not plateau after three years, either. A ten-year extension study published in the Journal of Bone and Mineral Research showed that bone mineral density continued to climb throughout a full decade of treatment, with fracture rates remaining low the entire time. In men with osteoporosis, Prolia produced a 5.7% increase in lumbar spine BMD compared to just 0.9% with placebo. Among prostate cancer patients undergoing androgen deprivation therapy — a treatment notorious for accelerating bone loss — denosumab delivered a 7.9% gain at the lumbar spine and 5.7% at the total hip over three years. These are the kinds of results that make endocrinologists enthusiastic. The problem is what happens when the injections stop.
The Rebound Effect — Why Stopping Prolia Can Trigger a Cascade of Fractures
Prolia works by blocking RANKL, a protein that activates the cells responsible for breaking down bone. As long as the drug is in the body, bone resorption slows dramatically. But denosumab does not permanently alter bone biology. It suppresses a process that roars back once the drug clears the system — and it clears fast. Within months of a missed or final dose, bone turnover markers spike above pre-treatment levels, and the bone density that took years to build can vanish in under a year. The Cleveland Clinic has documented cases of rapid bone loss and multiple vertebral fractures following denosumab cessation, warning clinicians that discontinuation itself constitutes a clinical event that must be managed.
The numbers are sobering. A systematic review found that patients who experienced rebound fractures after stopping Prolia averaged 4.7 vertebral fractures per person, occurring a mean of just 5.2 months after the drug’s effects wore off. New vertebral fractures have been documented as early as 7 months after the last injection, with cases appearing as late as 43 months out. The mean onset is around 17 months. However, if a patient simply delays their scheduled injection rather than stopping entirely, the risk still climbs sharply — missing the six-month dosing window is associated with a fourfold increased risk of vertebral fractures. This is a critical consideration for dementia patients, whose caregivers may struggle to maintain a strict biannual injection schedule. A forgotten appointment is not just a minor lapse; it is a fracture risk multiplier.
Why the Rebound Problem Matters More in Dementia Care
Dementia and osteoporosis frequently coexist in the same patient. Both conditions are age-related, both are progressive, and both are worsened by reduced mobility, poor nutrition, and the medications used to treat the other. Corticosteroids, sometimes prescribed for inflammatory conditions in older adults, accelerate bone loss. Antipsychotics and sedatives, often used to manage behavioral symptoms of dementia, increase fall risk. A patient with moderate Alzheimer’s who sustains multiple vertebral compression fractures is not simply dealing with back pain — they are facing immobilization, delirium from pain medications, potential hospitalization, and a steep decline in independence.
The rebound fracture phenomenon turns Prolia into a long-term commitment that is difficult to exit safely. International regulators have taken notice. The UK’s Medicines and Healthcare products Regulatory Agency and Australia’s Therapeutic Goods Administration have both issued strengthened warnings about fracture risk after discontinuation. In the United States, Public Citizen petitioned the FDA for a black box warning — the most serious safety label the agency can require — specifically citing the rebound fracture risk. For families managing a loved one’s care through the stages of dementia, starting Prolia means planning for years of reliable follow-through on a strict dosing schedule, or having a clear transition strategy to a bisphosphonate or another antiresorptive therapy if Prolia needs to be stopped.
What Does Prolia Cost, and Are Biosimilars a Realistic Alternative?
Cost is a practical barrier that shapes treatment decisions, especially for families already managing the financial burden of dementia care. Prolia’s retail price runs approximately $1,550 to $2,269 per injection without insurance, which translates to roughly $3,100 to $3,500 per year for the standard two-dose regimen. Amgen offers a copay assistance program that can bring the out-of-pocket cost down to as low as $25 per treatment for eligible patients, but not everyone qualifies, and Medicare patients are generally excluded from manufacturer copay cards. The landscape shifted meaningfully in mid-2025 when Sandoz launched the first U.S.
biosimilars to Prolia — Wyost and Jubbonti, both containing denosumab-bbdz — on June 2, 2025, priced 14.5% lower than the brand-name drug. Both received FDA interchangeability designations, meaning pharmacists in most states can substitute them without requiring a new prescription. Six additional denosumab biosimilars from Biocon, Hikma, and Shanghai Henlius/Organon were FDA-approved in August and September 2025. More competition typically drives prices lower over time, though how quickly patients and insurers see meaningful savings will depend on formulary negotiations. The tradeoff is clear: biosimilars offer the same efficacy and safety profile at a lower price, but they do not solve the fundamental rebound problem — stopping any denosumab product carries the same risks.
Side Effects Beyond the Rebound — What Else Should Patients and Caregivers Watch For?
The rebound fracture risk dominates the conversation around Prolia’s safety profile, but it is not the only concern. Hypocalcemia — dangerously low blood calcium levels — is a recognized side effect that can be life-threatening, particularly in patients with chronic kidney disease. Since many older adults with dementia also have impaired renal function, calcium and vitamin D levels must be monitored closely before and during treatment. Symptoms of hypocalcemia include muscle cramps, tingling in the fingers, and in severe cases, cardiac arrhythmias.
These symptoms can be difficult to identify in a patient who cannot reliably communicate what they are feeling. Prolia also carries risks of osteonecrosis of the jaw and atypical femoral fractures — the same rare but serious complications associated with bisphosphonates. The more common side effects reported in clinical trials include back pain, pain in the extremities, elevated cholesterol, and muscle pain. For a dementia patient who already has difficulty describing new symptoms, caregivers and clinicians need to be especially vigilant about monitoring for these adverse effects. Any new onset of jaw pain, thigh pain, or unexplained muscle cramping warrants prompt medical evaluation.
The Legal Landscape Around Prolia
Personal injury lawsuits have been filed against Amgen alleging that the company failed to adequately warn patients and physicians about the severity of rebound fracture risks upon discontinuation. These cases generally argue that the original labeling did not sufficiently convey how quickly and dramatically bone loss could accelerate after stopping the drug.
Separately, multiple biosimilar patent settlements between Amgen and competitors — including Celltrion, Samsung Bioepis, Biocon, Fresenius, and Accord — were reached throughout 2025, paving the way for the wave of lower-cost alternatives now entering the market. For patients who experienced serious fractures after stopping Prolia, consulting with a qualified attorney about their specific circumstances may be worthwhile.
What Comes Next for Bone Loss Treatment in Aging Populations
The arrival of biosimilars and growing awareness of the rebound fracture problem are reshaping how clinicians approach osteoporosis management in older adults. Current expert consensus recommends that patients who stop denosumab should transition to a bisphosphonate — typically zoledronic acid — to blunt the rebound effect, though the optimal timing and duration of that transition therapy remain subjects of active research.
For dementia care specifically, the field is moving toward more integrated treatment planning that accounts for a patient’s cognitive trajectory when making decisions about long-term injectable therapies. A drug that requires perfect adherence to a strict schedule is a different proposition for someone with mild cognitive impairment than it is for someone with advancing Alzheimer’s disease. The question is not whether Prolia works — the evidence on that point is overwhelming — but whether a given patient’s care network can sustain the commitment the drug demands.
Conclusion
Prolia remains one of the most effective treatments for osteoporosis, with decade-long data showing sustained bone density improvements and meaningful fracture reduction. The introduction of biosimilars in 2025 has begun to address the cost barrier, and for patients who can maintain the strict every-six-month dosing schedule, the drug delivers on its clinical promise. But the rebound fracture risk is real, well-documented, and particularly dangerous for older adults living with dementia — a population where medication adherence is fragile and a single fracture can set off a chain of decline.
Families and caregivers considering Prolia for a loved one with both osteoporosis and cognitive impairment should have a frank conversation with their physician about the long-term plan. That means not just whether to start the drug, but how to maintain the dosing schedule reliably, what the exit strategy looks like if treatment needs to stop, and whether the care team can commit to the monitoring the drug requires. The results are genuinely impressive. The catch is that walking away from those results can be worse than never starting.
Frequently Asked Questions
How often is Prolia injected?
Prolia is given as a single subcutaneous injection of 60 mg every six months. Staying on schedule is critical — delayed dosing is associated with a fourfold increased risk of vertebral fractures.
What happens if you stop taking Prolia?
Patients can lose all treatment-associated bone density gains within 12 months of stopping. Roughly 1 in 14 patients who discontinue without transitioning to another antiresorptive therapy experience rebound fractures, and up to 10% suffer multiple vertebral fractures. New fractures can appear as early as 7 months after the last dose.
Can a dementia patient safely take Prolia?
There is no cognitive contraindication to Prolia itself. The concern is practical — the drug requires strict adherence to a biannual injection schedule, and discontinuation carries serious risks. A reliable caregiver or care team must be in place to ensure appointments are not missed.
Are Prolia biosimilars just as effective?
Yes. The FDA-approved biosimilars Wyost and Jubbonti received interchangeability designations, meaning they meet the same standards for safety and efficacy as the brand-name drug. They are priced approximately 14.5% lower than Prolia.
What should you switch to if you stop Prolia?
Current expert guidance recommends transitioning to a bisphosphonate, most commonly zoledronic acid, to prevent the rebound bone loss that follows denosumab discontinuation. The timing and duration of transition therapy should be determined by your physician.
Does insurance cover Prolia?
Most insurance plans and Medicare Part B cover Prolia for approved indications. Without insurance, the cost ranges from approximately $1,550 to $2,269 per injection. Amgen’s copay program can reduce costs to as low as $25 per treatment for eligible commercially insured patients.
You Might Also Like
- Aimovig Injection for Migraines: Real Patients Share Their Results
- Why Risperdal Lawsuits Are Still Being Filed Decades Later
- Why Neurologists Are Excited About a New Once-Monthly Migraine Shot
For more, see Alzheimer’s Association — caregiving.
